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ddiction is a disease of neuroplasticity. In the
past, clinicians considered detoxification to be the treat-
ment for addiction. However, detoxification is simply
removal of the drug from the body and treatment of
withdrawal symptoms. Now we know that the essence of
addiction continues long after the last dose of the drug,
often lasting for years. This was first demonstrated in ani-
mal models, and later shown in human addicts more than
30 years ago.
1 Addiction is fundamentally a memory
trace that manifests itself by reflex activation of brain
circuits, especially the reward system, resulting in moti-
vation to resume drug-taking behavior when drug-
related cues are encountered.
Drugs that activate the reward system carry liability for
the development of addiction, but vulnerability to this
disorder is influenced by complex genetic and environ-
mental variables. A characteristic of all drugs that are
abused by humans is that they activate dopamine circuits
in brain reward systems by a variety of mechanisms. This
has been demonstrated directly in animal models and
indirectly in human brain imaging studies. Other neuro-
transmitters are also involved, but dopamine has
received the greatest attention. 
While a given drug of abuse will tend to have very simi-
lar immediate effects in all users, only a minority of users
progress to the stage of compulsive use or addiction. Two
general forms of neuroplasticity can be demonstrated.
The first, and most common, is tolerance accompanied by
physical dependence. Tolerance is manifested by reduced
effects from a given dose that is given repeatedly, and
“physical” dependence (not addiction) is manifested by
withdrawal symptoms when the drug is stopped abruptly.
This form of plasticity occurs in all individuals when cer-
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Compulsive drug-taking behavior develops in vulnerable
individuals who ingest substances that activate the reward
system. This intense activation produces learned associa-
tions to cues that predict drug availability. With repetition
the reward system becomes reflexively activated by cues
alone, leading to a drive toward drug-taking. The central
nervous system changes underlying this conditioned
behavior are just beginning to be understood. New treat-
ments aimed at this neuroplasticity are being tested in ani-
mal models. The clinical significance of these brain changes
is that addiction, once established, becomes a chronic ill-
ness with relapses and remissions. It therefore requires
chronic treatment with medications and behavioral ther-
apies based on an understanding of the fundamental
nature of these changes in the brain.
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tain drugs are taken repeatedly. Examples include pre-
scribed medications such as β-blockers, antidepressants,
sedatives, and opioids for pain, as well as commonly
abused drugs such as alcohol, cocaine, and nicotine.
The second form of neuroplasticity is manifested by
compulsive drug-seeking behavior. The reward system,
which developed early in evolution, reinforces adaptive
behavior such as that leading to the acquisition of water,
food, and sex. Drugs that directly activate the reward
system may produce learning that diverts the individual
to those behaviors that repeat the drug-induced feelings
of reward. An important feature of this form of neuro-
plasticity is that it is stable and perhaps permanent. The
dopamine release caused by a drug of abuse tends to be
greater than that of natural rewards, and to continue
with repeated exposure rather than diminish, as is the
case with natural, expected rewards.
2 Thus, the drug
experience becomes associated with environmental cues
and acquires increasing salience. Individuals who
develop this neuroplasticity tend to suffer from a chronic
illness with potential for relapse, even years after the last
dose of the drug. Drug-taking then acquires more
salience than natural or adaptive behaviors. 
Evidence of the plasticity that has occurred with the
development of addiction can be demonstrated by brain
imaging studies that show rapid activation (increased
blood flow to reward pathways) when drug-related cues
are shown to addicts who have been free of drugs for at
least a month.
3 Even cues so brief that they do not reach
consciousness (33 msec) can produce rapid activation.
4
During brain reward system activation, the addict
reports drug craving. The strength of the craving is
related directly to the amount of endogenous dopamine
released in reward structures, as measured by displace-
ment of labeled raclopride in positron emission tomog-
raphy (PET) studies.
5
More direct studies of the plasticity induced by drugs of
addiction can be seen in animal models. Shaham and col-
leagues have studied the relapse or reinstatement of
drug-taking in rats trained to self-administer intravenous
cocaine.
6Availability of cocaine is signaled by a light that
the animal then associates with cocaine. After the behav-
ior is well trained, the cocaine can be turned off; thus,
pushing the lever no longer provides cocaine. After the
extinction process is complete, the animal can be tested
for reinstatement by returning it to the drug-taking envi-
ronment and giving the light cue. This is considered to
be a model of “relapse” in human addicts. The intensity
of relapse can be measured by the number of times the
light causes the rat to press the bar despite not receiving
any cocaine. Eventually, the unrewarded bar pressing
stops. It was found that reinstatement occurred when
rats were tested 1 week after extinguishing cocaine-seek-
ing, but the reinstatement was significantly greater at 4
weeks, and progressively increased further if the rats
were allowed to rest in their cages for up to 6 months
before relapse testing. The strengthening of relapse ten-
dency over time has been called “incubation” and is
associated with increases in the levels of the growth fac-
tor brain-derived neurotrophic factor (BDNF) in the
ventral tegmental area and in the nucleus accumbens.
The authors also found that exposure to cocaine cues
increased extracellular signal-related kinase (ERK) in
central amygdala after 30 days of rest, but not after 1
day. This shows that there is an active neuroplastic
process in the brain that increases over time and is man-
ifested by increased cocaine-seeking behavior.
Transcription factors have been observed to be changed
by addictive drugs. Delta Fos B accumulates in dopamine
terminals in the cortex and striatum.
7All drugs of abuse
tested produce an increase in delta Fos B, which appears
to be involved in the development of motivated behav-
iors. Disruption of this process blocks the development
of drug-associated plasticity such as behavioral sensiti-
zation. The latter is the increase in motor behavior in
response to repeated, fixed doses of a stimulant.
8 Genes
directly regulated by delta Fos B appear to have differ-
ent effects and may limit as well as promote drug rein-
forcement. The delta Fos B changes are temporary, with
return to prior levels when the drug is no longer present.
Thus, these transcription factor changes do not seem to
underlie long-term neuroplasticity.
Changes in neuronal morphology have also been noted
in animals exposed to drugs that are abused. In the
nucleus accumbens, an increase in dendritic spine den-
sity has been reported in medium spiny neurons from
rats self-administering cocaine. These changes persisted
during abstinence, and may be involved in long-term
changes associated with drug-seeking behavior.
9
Changes in neuronal morphology have also been found
in individuals chronically exposed to opioids. Chronic
morphine given to rats, for example, has been found to
reduce dendritic spines (whereas stimulants increased
spines) on ventral tegmental area neurons. Chronic mor-
phine also reduces neurogenesis in the hippocampus.
10
These changes may be the basis for the cognitive losses
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seen in some patients receiving chronic opioids for pain.
Since the learned addictive behavior is thought to result
from neuroplasticity such as that described above, it seems
logical to consider reversal of these changes as a target for
the treatment of addictive behaviors. A very interesting ani-
mal model of this approach has been illustrated by a series
of experiments by Kalivas et al. Using rats trained to self-
administer cocaine, they reported a reduction in glutamate
in the brains of animals exposed to long-term cocaine and
a disruption of glutamate homeostasis. Following with-
drawal from chronic cocaine there is a marked imbalance
in glutamate homeostasis, with both cystine-glutamate
exchange and glutamate uptake being reduced in the
nucleus accumbens.
11The imbalance in glutamate home-
ostasis is associated with a reduction in basal extracellular
glutamate levels and a potentiated release of synaptic glu-
tamate during drug-seeking.
12 In addition, there is a basal
increase in the α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA) to N-methyl-D-aspartic acid
(NMDA) current ratio and a loss of both long-term poten-
tiation (LTP) and long-term depression (LTD).
13
There are therapeutic implications in these observations
on glutamate homeostasis. Cystine can be administered
to animals withdrawn from chronic cocaine using N-
acetylcysteine as a carrier, or glutamate uptake can be
increased by the antibiotic ceftriaxone. By restoring the
glutamate homeostasis in this manner, reinstatement of
cocaine seeking is prevented. The treated animals also
show a restored ability to induce LTP and LTD, as well
as a normalization of the AMPA:NMDA ratio. The treat-
ment also prevents changes in spine head diameter
induced during cocaine-seeking.
13
Taken together, the data above suggest the possibility
that normalization of glutamate homeostasis in addicts
might restore the ability to induce synaptic plasticity in
the nucleus accumbens, which in turn could facilitate
establishing behaviors that might compete with drug-
seeking. 
Exogenous N-acetyl cysteine is used for the treatment
of hepatic failure in acetaminophen overdose. Thus, it
was available to be administered to cocaine addicts pre-
sented with cocaine-related cues in an attempt to trans-
late findings in the animal model to human addicts.
Those treated with N-acetyl cysteine reported reduced
desire for cocaine compared with the control group.
14 In
another human study, N-acetyl cysteine was found to
reduce pathological gambling
15 and cigarette smoking.
16
Further clinical trials are in progress.
Another attempt to reverse the learned behaviors seen
in addiction involves a new technology of real-time func-
tional magnetic resonance imaging biofeedback of brain
activity.
17Addicts have been shown to have poor ability
to inhibit impulses, and this correlates with decreased
frontal lobe activity. Normal subjects can activate frontal
control mechanisms when attempting to inhibit sexual
arousal, but cocaine-dependent patients are unable to
inhibit craving when shown drug-related stimuli. By pro-
viding feedback of frontal activation, the patients will
attempt to learn to activate inhibitory structures and
inhibit drug craving. This represents a therapeutic
attempt to introduce new learning to control addictive
behavior. The continued study of the underlying mech-
anisms of plasticity will undoubtedly produce other
novel pharmacological and behavioral treatments.❏
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 352353 www.dialogues-cns.org
REFERENCES
1. O'Brien CP, Testa T, O'Brien TJ, Brady JP, Wells B. Conditioned narcotic
withdrawal in humans. Science. 1977;195:1000-1002.
2. Schultz W. Predictive reward signal of dopamine neurons. Am J
Physiol. 1998;80:1–27.
3. Childress AE, Mozley PD, McElgin W, Fitzgerald J, Revich M, O’Brien
CP. Limbic activation during cue-induced cocaine craving. Am J Psych.
1999;156:11-18.
4. Childress AR, Ehrman. RN, Wang Z, et al. Prelude to passion: limbic
activation by “unseen” drug and sexual cues. PLoS ONE. 2008;3:e1506.
5. Volkow ND, Wang G-J, Teland F, et al. Cocaine cues and dopamine in
dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci.
2006;26:6583-6588.
6. Grimm JW, Hope BT, Wise RA, Shaham Y. Neuroadaptation.
Incubation of cocaine craving after withdrawal. Nature. 2001;412:141-142.
7. McClung CA, Nestler EJ. Regulation of gene expression and cocaine
reward by CREB and DeltaFosB. Nat Neurosci. 2003;6:1208–1215.
8. Nestler E. Molecular basis of long-term plasticity underlying addic-
tion. Nat Rev. 2001;2:119–128.
9. Robinson TE, Kolb B. Structural plasticity associated with exposure to
drugs of abuse. Neuropharmacology. 2004;47(suppl 1):33–46.
10. Eisch AJ, Barrot M, Schad, CA, Self DW, Nestler EJ. Opiates inhibit
neurogenesis in the adult rodent dentate gyrus. Proc Natl Acad Sci U S A.
2000;97:7579-7584.
11. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine–
glutamate exchange underlie cocaine relapse. Nat Neurosci. 2003;6:743–
749.
12. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into
the core of the nucleus accumbens mediates cocaine-induced reinstate-
ment of drug-seeking behavior. J Neurosci. 2003;23:3531–3537.
13.  Shen H-W, Toda S, Moussawi K, Bouknight A, Zahm DS, Kalivas PW.
Altered dendritic spine plasticity in cocaine-withdrawn rats. J Neurosci.
2009;29;2876-2884.
14.  LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by
N-acetylcysteine? Am J Psych. 2007;164:1115-1117.
15.  Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modu-
lating agent, in the treatment of pathological gambling: a pilot study. Biol
Psych. 2007;62:652-657. 
16.  Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystine-glu-
tamate exchange in nicotine dependence in rats and humans. Biol Psych.
2008;65;841-845.
17.  deCharms RC. Applications of real-time fMRI. Nat Rev Neurosci.
2008;9:720-729.
Neuroplasticidad en los trastornos adictivos
La conducta compulsiva de consumir drogas se
desarrolla en individuos vulnerables que ingieren
sustancias que activan el sistema de recompensa.
Esta intensa activación produce asociaciones apren-
didas frente a señales que predicen la disponibili-
dad de droga. Con la repetición, el sistema de
recompensa se activa en forma refleja sólo por las
señales, favoreciendo el camino hacia el consumo
de drogas. Recién se están comenzando a com-
prender los cambios del sistema nervioso central
que subyacen a esta conducta condicionada. En
modelos animales se están evaluando nuevos tra-
tamientos  orientados a esta neuroplasticidad. El
significado clínico de estos cambios cerebrales es
que la adicción, una vez establecida, llega a ser una
enfermedad crónica con recaídas y remisiones. Esta
patología requiere por lo tanto de un tratamiento
crónico con medicamentos y terapias conductuales
basadas en una comprensión de la naturaleza fun-
damental de estos cambios en el cerebro. 
Neuroplasticité et troubles addictifs
Les comportements compulsifs de prise de sub-
stance se développent chez des individus vulné-
rables qui ingèrent des substances activant le sys-
tème de récompense. Cette activation intense
entraîne des associations  à des signaux qui indi-
quent la disponibilité de la drogue par un phéno-
mène d’apprentissage. Avec les répétitions du pro-
cessus, le système de récompense s’active de façon
réflexe par les seuls signaux, provoquant une pul-
sion de prise de drogue. Les modifications du sys-
tème nerveux central qui sous-tendent ce compor-
tement conditionné commencent seulement à être
comprises. De nouveaux traitements ciblant cette
neuroplasticité sont en train d’être testés dans des
modèles animaux. Ces modifications cérébrales
signifient cliniquement que l’addiction, une fois ins-
tallée, se comporte comme une maladie chronique
avec rechutes et rémissions. Ceci nécessite donc un
traitement chronique avec des médicaments et des
thérapies comportementales basées sur la compré-
hension de la nature fondamentale de ces modifi-
cations cérébrales.
Neuroplasticity in addictive disorders - O’Brien Dialogues in Clinical Neuroscience - Vol 11 . No. 3 . 2009
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 353